None

CSL Behring obtains expanded label approval for Berinert in Europe

CSL Behring has obtained expanded label approval for a C1-esterase inhibitor (C1-INH) concentrate, Berinert, for short-term prophylaxis in adults and children with hereditary angioedema (HAE) in 23 Eu...

CSL Behring's Berinert OKed in Europe for short-term prophylaxis in HAE

Germany-based CSL Behring, a unit of Australia's CSL Ltd (ASX: CSL) says that European health authorities have approved an extended use of Berinert, a C1-esterase inhibitor (C1-INH) concentrate, for p...

Berinert regulatory update

CSL Behring Launches Co-Pay Assistance Program For Berinert

Program provides commercially insured patients with up to $12,000 a year in eligible expenses for C1 esterase inhibitor Berinert, used to treat the rare disease hereditary angioedema.

CSL Behring Receives European Health Authorities' Approval of Berinert® for Short-Term Prophylaxis in Adults and Children

MARBURG, Germany, April 16, 2013 /PRNewswire/ -- CSL Behring today announced that European health authorities have approved an extended use of Berinert®, a C1-esterase inhibitor (C1-INH) con...

CSL Behring Launches Its First Co-Pay Assistance Program to Ease Financial Burden of Treating Hereditary Angioedema

KING OF PRUSSIA, Pa., Jan. 2, 2013 /PRNewswire/ -- CSL Behring announced today the launch of a financial assistance program designed to cover patients' out-of-pocket expenses for Beri...

PM360 Magazine Announces Winners of 2012 Trailblazer Awards

Best of the Best in Healthcare Marketing Honored at Gala Event New York, NY (PRWEB) September 26, 2012 PM360, a leading health-marketing industry trade magazine, recognized the best innovators in the...

PM360 Judges Announce 2012 Trailblazer Award Finalists

Top Healthcare Talent, Companies and Brands to be Honored September 21st New York, NY (PRWEB) August 14, 2012 The finalists are in for the fourth-annual PM360 Trailblazer Awards. PM360, a leading hea...

Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary Angioedema.

INTRODUCTION: Hereditary angioedema (HAE) is a rare disorder characterized by C1 esterase inhibitor (C1-INH) deficiency, resulting in periodic attacks of acute edema that can be life-threatening if th...

Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks.

BACKGROUND: C1 esterase inhibitor (C1-INH) replacement is recommended as a first-line therapy for acute edema attacks in hereditary angioedema (HAE). Only limited pharmacokinetic analyses of the admin...

C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 study.

To cite this article: Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, Moy JN, Offenberger J, Jacobson KW, Yang WH, Eidelman F, Janss G, Packer FR, Rojavin MA, Machnig T, Keinecke H-O...